Business Context and Reporting Period
CalciMedica, Inc. (CALC) filed a Current Report on Form 8-K on August 27, 2026. The filing announces a corporate action approved by stockholders at the 2026 Annual Meeting on August 19, 2026, and by the Board of Directors on the same date.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a capital structure adjustment.
Material Changes
- Reverse Stock Split: A one-for-five (1-for-5) reverse stock split of outstanding common stock.
- Authorized Shares Reduction: The total number of authorized common shares is reduced from 500,000,000 to 100,000,000.
- Effective Date: The amendment becomes effective at 5:00 p.m. Eastern Time on August 28, 2026.
- Trading Resumption: Stock will resume trading on The Nasdaq Capital Market under the ticker "CALC" on a split-adjusted basis on August 31, 2026.
- New CUSIP: The new CUSIP number is 38942Q301.
Guidance, Outlook, and Management Commentary
The filing does not provide forward-looking guidance, management commentary on financial outlook, or discussion of risks and contingencies beyond the mechanics of the stock split. The Company notes that the split will not affect any stockholder's percentage ownership, except where fractional shares are involved. Fractional shares will not be issued; instead, stockholders entitled to fractional shares will receive a cash payment in lieu thereof.
Proportionate adjustments will be made to:
- Per share exercise prices and share counts for outstanding stock options.
- Outstanding restricted stock unit awards and warrants.
- The number of shares reserved for issuance under equity compensation plans.
Investor Verification Checklist
- Verify the effective time of the reverse stock split (August 28, 2026, 5:00 p.m. ET).
- Confirm the new CUSIP number (38942Q301) for trading purposes starting August 31, 2026.
- Review the treatment of fractional shares (cash payment in lieu of issuance).
- Check the impact on existing equity awards (options, RSUs, warrants) regarding adjusted exercise prices and share counts.
- Confirm the reduction in authorized shares from 500 million to 100 million.